Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 713

Similar articles for PubMed (Select 19100916)

1.

A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma.

Chi DS, Zivanovic O, Palayekar MJ, Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Levine DA, Leitao MM, Brown CL, Barakat RR.

Gynecol Oncol. 2009 Jan;112(1):6-10. doi: 10.1016/j.ygyno.2008.10.010.

PMID:
19100916
2.

The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer.

Zivanovic O, Eisenhauer EL, Zhou Q, Iasonos A, Sabbatini P, Sonoda Y, Abu-Rustum NR, Barakat RR, Chi DS.

Gynecol Oncol. 2008 Feb;108(2):287-92. Epub 2007 Nov 13.

PMID:
17996927
3.

CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer.

Memarzadeh S, Lee SB, Berek JS, Farias-Eisner R.

Int J Gynecol Cancer. 2003 Mar-Apr;13(2):120-4.

PMID:
12657110
4.

Can serum CA-125 levels predict the optimal primary cytoreduction in patients with advanced ovarian carcinoma?

Saygili U, Guclu S, Uslu T, Erten O, Demir N, Onvural A.

Gynecol Oncol. 2002 Jul;86(1):57-61.

PMID:
12079301
5.

The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma.

Chi DS, Venkatraman ES, Masson V, Hoskins WJ.

Gynecol Oncol. 2000 May;77(2):227-31.

PMID:
10785469
6.

Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach.

Chi DS, Franklin CC, Levine DA, Akselrod F, Sabbatini P, Jarnagin WR, DeMatteo R, Poynor EA, Abu-Rustum NR, Barakat RR.

Gynecol Oncol. 2004 Sep;94(3):650-4.

PMID:
15350354
7.

The incidence of major complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas.

Chi DS, Zivanovic O, Levinson KL, Kolev V, Huh J, Dottino J, Gardner GJ, Leitao MM Jr, Levine DA, Sonoda Y, Abu-Rustum NR, Brown CL, Barakat RR.

Gynecol Oncol. 2010 Oct;119(1):38-42. doi: 10.1016/j.ygyno.2010.05.031. Epub 2010 Jul 6.

PMID:
20609464
8.

Maximal cytoreduction in patients with FIGO stage IIIC to stage IV ovarian, fallopian, and peritoneal cancer in day-to-day practice: a Retrospective French Multicentric Study.

Luyckx M, Leblanc E, Filleron T, Morice P, Darai E, Classe JM, Ferron G, Stoeckle E, Pomel C, Vinet B, Chereau E, Bergzoll C, Querleu D.

Int J Gynecol Cancer. 2012 Oct;22(8):1337-43.

PMID:
22964527
9.

A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography.

Bristow RE, Duska LR, Lambrou NC, Fishman EK, O'Neill MJ, Trimble EL, Montz FJ.

Cancer. 2000 Oct 1;89(7):1532-40.

PMID:
11013368
10.

Can the preoperative Ca-125 level predict optimal cytoreduction in patients with advanced ovarian carcinoma? A single institution cohort study.

Vorgias G, Iavazzo C, Savvopoulos P, Myriokefalitaki E, Katsoulis M, Kalinoglou N, Akrivos T.

Gynecol Oncol. 2009 Jan;112(1):11-5.

PMID:
19119502
11.
12.

A retrospective study of preoperative CA 125 levels in 82 patients with ovarian cancer.

Rossi AC, Di Vagno G, Cormio G, Cazzolla A, Stefanelli S, D'Elia E, Selvaggi L.

Arch Gynecol Obstet. 2004 May;269(4):263-5. Epub 2004 Jan 24.

PMID:
14745561
13.

Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: Surgical and oncological outcomes. Single institution experience.

Peiretti M, Zanagnolo V, Aletti GD, Bocciolone L, Colombo N, Landoni F, Minig L, Biffi R, Radice D, Maggioni A.

Gynecol Oncol. 2010 Nov;119(2):259-64. doi: 10.1016/j.ygyno.2010.07.032. Epub 2010 Aug 25.

PMID:
20800269
14.

Follow-up study of the correlation between postoperative computed tomographic scan and primary surgeon assessment in patients with advanced ovarian, tubal, or peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual disease of 1 cm or smaller.

Chi DS, Barlin JN, Ramirez PT, Levenback CF, Mironov S, Sarasohn DM, Iyer RB, Dao F, Hricak H, Barakat RR.

Int J Gynecol Cancer. 2010 Apr;20(3):353-7. doi: 10.1111/IGC.0b013e3181d09fd6.

PMID:
20375796
15.

Factors associated with cytoreducibility among women with ovarian carcinoma.

Eltabbakh GH, Mount SL, Beatty B, Simmons-Arnold L, Cooper K, Morgan A.

Gynecol Oncol. 2004 Nov;95(2):377-83.

PMID:
15491760
16.

What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?

Chi DS, Eisenhauer EL, Lang J, Huh J, Haddad L, Abu-Rustum NR, Sonoda Y, Levine DA, Hensley M, Barakat RR.

Gynecol Oncol. 2006 Nov;103(2):559-64. Epub 2006 May 22.

PMID:
16714056
17.

Beyond tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Shih KK, Chi DS, Barakat RR, Leitao MM Jr.

Gynecol Oncol. 2010 Mar;116(3):364-9. doi: 10.1016/j.ygyno.2009.10.047. Epub 2009 Nov 7.

PMID:
19897231
18.

Can optimal primary cytoreduction be predicted in advanced stage epithelial ovarian cancer? Role of preoperative serum CA-125 level.

Obeidat B, Latimer J, Crawford R.

Gynecol Obstet Invest. 2004;57(3):153-6. Epub 2004 Jan 15.

PMID:
14726621
19.

A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer.

Suidan RS, Ramirez PT, Sarasohn DM, Teitcher JB, Mironov S, Iyer RB, Zhou Q, Iasonos A, Paul H, Hosaka M, Aghajanian CA, Leitao MM Jr, Gardner GJ, Abu-Rustum NR, Sonoda Y, Levine DA, Hricak H, Chi DS.

Gynecol Oncol. 2014 Sep;134(3):455-61. doi: 10.1016/j.ygyno.2014.07.002. Epub 2014 Jul 11.

PMID:
25019568
20.

Prospective study of the correlation between postoperative computed tomography scan and primary surgeon assessment in patients with advanced ovarian, tubal, and peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual disease 1 cm or less.

Chi DS, Ramirez PT, Teitcher JB, Mironov S, Sarasohn DM, Iyer RB, Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Levine DA, Brown CL, Aghajanian C, Gershenson DM, Hoskins WJ, Hricak H, Barakat RR.

J Clin Oncol. 2007 Nov 1;25(31):4946-51.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk